KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer

MLA

Chloe E. Atreya, et al. “KEYNOTE-164: Pembrolizumab for Patients with Advanced Microsatellite Instability High (MSI-H) Colorectal Cancer.” Journal of Clinical Oncology, vol. 36, May 2018, p. 3514. EBSCOhost, https://doi.org/10.1200/jco.2018.36.15_suppl.3514.

APA

Chloe E. Atreya, Tong Dai, Patrick McKay Boland, Jean-Luc Van Laethem, Dung T. Le, Matthew Burge, Tae Won Kim, Hiroki Hara, Bert H. O’Neil, Eric Van Cutsem, Todd S. Crocenzi, L. Liang, Petr Kavan, Patricia Marinello, Hiroya Taniguchi, Luis A. Diaz, Manish R. Sharma, & Ravit Geva. (2018). KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. Journal of Clinical Oncology, 36, 3514. https://doi.org/10.1200/jco.2018.36.15_suppl.3514

Chicago

Chloe E. Atreya, Tong Dai, Patrick McKay Boland, Jean-Luc Van Laethem, Dung T. Le, Matthew Burge, Tae Won Kim, et al. 2018. “KEYNOTE-164: Pembrolizumab for Patients with Advanced Microsatellite Instability High (MSI-H) Colorectal Cancer.” Journal of Clinical Oncology 36 (May): 3514. doi:10.1200/jco.2018.36.15_suppl.3514.